Navigation Links
Phase Genomics Announces Availability of Kit-based ProxiMeta™ Hi-C Metagenome Deconvolution
Date:10/7/2017

Phase Genomics, the industry leader in Hi-C-based genomic technologies, launched its ProxiMeta™ Hi-C metagenome deconvolution product, featuring the first commercially available Hi-C kit. Researchers can use the ProxiMeta Hi-C kit and accompanying cloud-based bioinformatics software to perform Hi-C metagenome deconvolution using their own facilities, supplementing the company’s full-service ProxiMeta offering launched in May 2017. Additionally, a newly available paper demonstrates the technology’s power to assemble over 250 genomes from a single human fecal sample.

“Using the ProxiMeta kit and our computational tools, researchers can now assemble numerous high-quality genomes from mixed samples without culturing, high-molecular-weight DNA extraction, or any a priori information,” said Dr. Ivan Liachko, CEO of Phase Genomics. “The applications of this technology are broad and exciting, and we’ve shown that ProxiMeta can be used to discover many novel species, detect plasmid-host interactions, and identify strain-level genetic variation. We are even more excited to see all the discoveries that this technology will enable as it is adopted by the wider scientific community.”

Microbiome samples are made up of many different microorganisms that must be sequenced together. A key challenge in metagenomics is determining which DNA sequences originated from which organism in the mix. ProxiMeta solves this problem using an enhanced version of the chromatin capture technique Hi-C, which measures the physical structure of microbial genomes while their cells are still intact.

This powerful innovation enables researchers to study individual microbial communities with unprecedented precision, opening the door to deeper, more rapid discoveries in fields like the microbiome, infectious disease, agriculture, and antibiotic resistance.

"Phase Genomics' ProxiMeta Hi-C solution makes innovative use of Illumina reads to conduct metagenomic deconvolution and extract more complete sequence information from mixed microbiome samples,” said Gary Schroth, PhD, Vice President of Genomics Development and Distinguished Scientist for Illumina. “This technology promises to open many new metagenomic applications and we’re excited to see it come to market."

ProxiMeta™ includes a kit for sample processing, cloud-based software for analysis, and full customer support. For more information, email your inquiry to info(at)phasegenomics(dot)com or visit their website at http://www.phasegenomics.com.

Read the full story at http://www.prweb.com/releases/2017/10/prweb14776751.htm.


'/>"/>
Source: PRWeb
Copyright©2017 Vocus, Inc.
All rights reserved


Related biology technology :

1. Multidisciplinary Association for Psychedelic Studies (MAPS) Selects Montriums eTMF Platform as They Begin Phase 3 Studies of MDMA-assisted Psychotherapy for PTSD
2. GeneOne Life Science Receives Approval for Phase I/IIa MERS-CoV Vaccine Trial in Korea
3. SFC Fluidics, Inc. Receives SBIR Phase II Funding for Development of an Implantable Drug Delivery Device
4. Allotrope Foundation Achieves Two Major Milestones: Releases 1st Phase of Framework for Commercial Use and is Recognized with a 2017 Bio-IT World Best Practice Award
5. Worldwide Clinical Trials Selected by BrainStorm as CRO for Phase 3 NurOwn Trial in ALS
6. ACEA Biosciences Announces Successful Completion of Phase I Clinical Study of Novel Autoimmune Disease Drug
7. Three Phase 1 Ventures Participants Receive Science Center Funding
8. Sentien Biotechnologies, Inc. Announces Open Enrollment in Phase 1/2 Trial of SBI-101 for Patients with Acute Kidney Injury
9. JDP Initiates Pivotal Phase 3 Clinical Trial of JDP-205 for Acute Urticaria
10. Phase Genomics Announces the Commercial Availability of ProxiMeta™ Hi-C
11. Lilly Announces Positive Results for Three Phase 3 Studies of Galcanezumab for the Prevention of Episodic and Chronic Migraine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2018)... ... August 01, 2018 , ... ... results on the significant impact of a proprietary biofield energy treated supplement ... preclinical research assessed biomarkers for systemic and organ-specific inflammation, as well as, ...
(Date:7/31/2018)... N.Y. (PRWEB) , ... July 31, 2018 , ... ... of 2 additional CE/IVD marked molecular quality controls to its expanding CE/IVD product ... quality controls to our expanding CE/IVD QC offerings. ZeptoMetrix remains entirely committed to ...
(Date:7/27/2018)... ... July 27, 2018 , ... Representatives of ... Biotechnology Innovation Organization (BIO) met with U.S. Environmental Protection Agency (EPA) staff ... Substances Control Act (TSCA) Inventory Representation and Equivalency Determinations for Renewable and ...
(Date:7/25/2018)... ... July 25, 2018 , ... Eileen ... impact of a biofield energy treated nutraceutical to improve skin health parameters including ... for skin health and reported the following results:,     More ...
Breaking Biology Technology:
(Date:7/31/2018)... ... July 31, 2018 , ... ACEA Biosciences, is a privately owned ... has just introduced the xCELLigence RTCA S16, which the ideal entry level model for ... computer, the S16can be placed in any standard CO2 tissue culture incubator. The ...
(Date:7/31/2018)... ... July 31, 2018 , ... Lifecycle Biotechnologies, ... Business Development Manager. In this role, Mr. Muzek will lead the company-wide industrial ... growth and expansion. , With over 20 years in business development, Mr. ...
(Date:7/30/2018)... ... 2018 , ... TC Slade, an evidence-based healer, today released ... treated Vitamin D3 on the strength and health of bones. , The ... ALP, a bone-specific enzyme ,     Over 240% increase in collagen levels , ...
Breaking Biology News(10 mins):